Report Overview

The EU Soft Tissue Sarcoma Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of a human body such as fat, muscle, nerves, fibrous tissues, or deep skin tissues. About 40 percent of the cases occur in the legs usually at or above the knee. Fifteen percent develop in the hands and arms, another 15 percent in the head and neck and remaining 30 percent in the shoulders, chest, abdomen, or hips. Treatment are of different types for different cases, depending on the size, location, extent and grade (growth rate) of the tumour, owing to which, combination of all or some of these treatments may be used



Market Drivers

Europe soft tissue sarcoma market is expected to observe a formidable rate of growth, as the region is witnessing a significant rise in number of patients suffering from soft tissue sarcoma. The advent of advanced therapies such as targeted and biological are also acting as a major supporting factor for the market growth. Furthermore, increase in funding provided by European Union for research & development of more effective drugs and therapies to cure soft tissue sarcoma is one of the key factors compelling more manufacturers to enter the market. The Europe soft tissue sarcoma market is poised to undergo significant growth during the forecast period owing to the increase in approval for manufacture of generic drugs and need to deliver quality in patient care